

Erica L Carpenter

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2746919/publications.pdf>

Version: 2024-02-01

58
papers

2,800
citations

304743

22
h-index

182427

51
g-index

60
all docs

60
docs citations

60
times ranked

5061
citing authors

#	ARTICLE	IF	CITATIONS
1	<i>MYC</i> Levels Regulate Metastatic Heterogeneity in Pancreatic Adenocarcinoma. <i>Cancer Discovery</i> , 2022, 12, 542-561.	9.4	35
2	Reduced ER-mitochondria connectivity promotes neuroblastoma multidrug resistance. <i>EMBO Journal</i> , 2022, 41, e108272.	7.8	16
3	PSMA-targeting TGF β -insensitive armored CAR cells in metastatic castration-resistant prostate cancer: a phase 1 trial. <i>Nature Medicine</i> , 2022, 28, 724-734.	30.7	171
4	Plasma Genotyping at the Time of Diagnostic Tissue Biopsy Decreases Time-to-Treatment in Patients With Advanced NSCLC Results From a Prospective Pilot Study. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100301.	1.1	7
5	Biomarker Testing, Treatment Uptake, and Survival Among Patients With Urothelial Cancer Receiving Gene-Targeted Therapy. <i>JAMA Oncology</i> , 2022, 8, 1070.	7.1	2
6	Extracellular Vesicle-Based Multianalyte Liquid Biopsy as a Diagnostic for Cancer. <i>Annual Review of Biomedical Data Science</i> , 2022, 5, 269-292.	6.5	6
7	Association of comprehensive molecular genotyping and overall survival in patients with advanced non-squamous non-small cell lung cancer. <i>Journal of Clinical Oncology</i> , 2022, 40, 9022-9022.	1.6	10
8	Development of a robust radiomic biomarker of progression-free survival in advanced non-small cell lung cancer patients treated with first-line immunotherapy. <i>Scientific Reports</i> , 2022, 12, .	3.3	6
9	Circulating <i>KRAS</i> variant-specific shedding and association with survival in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) receiving chemoimmunotherapy. <i>Journal of Clinical Oncology</i> , 2022, 40, 2548-2548.	1.6	0
10	Blood-based gene expression signature associated with metastatic castrate-resistant prostate cancer patient response to abiraterone plus prednisone or enzalutamide. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 448-456.	3.9	0
11	THBS2/CA19-9 Detecting Pancreatic Ductal Adenocarcinoma at Diagnosis Underperforms in Prediagnostic Detection: Implications for Biomarker Advancement. <i>Cancer Prevention Research</i> , 2021, 14, 223-232.	1.5	13
12	A Pilot Study of Galunisertib plus Stereotactic Body Radiotherapy in Patients with Advanced Hepatocellular Carcinoma. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 389-397.	4.1	7
13	CD40 agonistic monoclonal antibody APX005M (sotigalimab) and chemotherapy, with or without nivolumab, for the treatment of metastatic pancreatic adenocarcinoma: an open-label, multicentre, phase 1b study. <i>Lancet Oncology</i> , The, 2021, 22, 118-131.	10.7	177
14	A phase I clinical trial of PSMA-directed/TGF β -insensitive CAR-T cells in metastatic castration-resistant prostate cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 125-125.	1.6	12
15	Plasma Tumor Mutation Burden and Response to Pembrolizumab Response. <i>Clinical Cancer Research</i> , 2021, 27, 1581-1581.	7.0	2
16	Systemic inflammation is a determinant of outcomes of CD40 agonist-based therapy in pancreatic cancer patients. <i>JCI Insight</i> , 2021, 6, .	5.0	14
17	Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy. <i>JCO Precision Oncology</i> , 2021, 5, 510-524.	3.0	36
18	Combining radiomic phenotypes of non-small cell lung cancer with liquid biopsy data may improve prediction of response to EGFR inhibitors. <i>Scientific Reports</i> , 2021, 11, 9984.	3.3	13

#	ARTICLE	IF	CITATIONS
19	Nanoanalysis of plasma volatile organic compounds using novel DNA-decorated carbon nanotube vapor sensors to noninvasively distinguish ovarian and pancreatic cancer from benign and control samples.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5544-5544.	1.6	1
20	Plasma Cell-Free DNA Genotyping: From an Emerging Concept to a Standard-of-Care Tool in Metastatic Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2021, 26, e1812-e1821.	3.7	15
21	Optimization of Sources of Circulating Cell-Free DNA Variability for Downstream Molecular Analysis. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1545-1552.	2.8	4
22	EUS-based Pancreatic Cancer Surveillance in <i>BRCA1/BRCA2/PALB2/ATM</i> Carriers Without a Family History of Pancreatic Cancer. <i>Cancer Prevention Research</i> , 2021, 14, 1033-1040.	1.5	5
23	Incorporation of plasma-based next-generation sequencing to improve guideline-concordant molecular testing in patients with newly diagnosed metastatic nonsquamous non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 14-14.	1.6	1
24	Association of plasma cell-free DNA with survival in patients with IDH wild-type glioblastoma. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab011.	0.7	10
25	THSB2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma. <i>Oncotarget</i> , 2021, 12, 2266-2272.	1.8	1
26	Racial Disparities in 30-Day Outcomes Following Index Admission for COVID-19. <i>Frontiers in Medicine</i> , 2021, 8, 750650.	2.6	2
27	Impact of Interobserver Variability in Manual Segmentation of Non-Small Cell Lung Cancer (NSCLC) Applying Low-Rank Radiomic Representation on Computed Tomography. <i>Cancers</i> , 2021, 13, 5985.	3.7	7
28	Clinical Utility of Plasma Cell-Free DNA in Adult Patients with Newly Diagnosed Glioblastoma: A Pilot Prospective Study. <i>Clinical Cancer Research</i> , 2020, 26, 397-407.	7.0	63
29	Highly specific enrichment of rare nucleic acid fractions using <i>Thermus thermophilus</i> argonaute with applications in cancer diagnostics. <i>Nucleic Acids Research</i> , 2020, 48, e19-e19.	14.5	76
30	Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	113
31	Plasma cfDNA in Glioblastomaâ€”Response. <i>Clinical Cancer Research</i> , 2020, 26, 2276-2276.	7.0	0
32	Baseline Plasma Tumor Mutation Burden Predicts Response to Pembrolizumab-based Therapy in Patients with Metastatic Nonâ€”Small Cell Lung Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2354-2361.	7.0	70
33	A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2020, 26, 3248-3258.	7.0	64
34	Impact of <i>KRAS</i> and <i>TP53</i> Co-Mutations on Outcomes After First-Line Systemic Therapy Among Patients With <i>STK11</i> -Mutated Advanced Nonâ€”Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2019, 3, 1-11.	3.0	46
35	Hepatocytes direct the formation of a pro-metastatic niche in the liver. <i>Nature</i> , 2019, 567, 249-252.	27.8	263
36	Measurement and immunophenotyping of pleural fluid EpCAM-positive cells and clusters for the management of non-small cell lung cancer patients. <i>Lung Cancer</i> , 2019, 127, 25-33.	2.0	13

#	ARTICLE	IF	CITATIONS
37	Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer. <i>JAMA Oncology</i> , 2019, 5, 173.	7.1	334
38	Flow based single cell analysis of the immune landscape distinguishes Barrett's esophagus from adjacent normal tissue. <i>Oncotarget</i> , 2019, 10, 3592-3604.	1.8	7
39	Rare Event Phenotyping and Molecular Characterization: Circulating Tumor Cells. <i>Methods in Molecular Biology</i> , 2019, 2032, 213-226.	0.9	0
40	An integrated flow cytometry-based platform for isolation and molecular characterization of circulating tumor single cells and clusters. <i>Scientific Reports</i> , 2018, 8, 5035.	3.3	63
41	Feasibility of monitoring advanced melanoma patients using cell-free cfDNA from plasma. <i>Pigment Cell and Melanoma Research</i> , 2018, 31, 73-81.	3.3	25
42	Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer. <i>JCO Precision Oncology</i> , 2018, 2018, 1-29.	3.0	49
43	PATH-41. PLASMA CELL-FREE DNA (cfDNA) CONCENTRATION IS INDEPENDENTLY ASSOCIATED WITH RADIOGRAPHIC TUMOR BURDEN IN NEWLY DIAGNOSED GLIOBLASTOMA (GBM) PRIOR TO INITIAL SURGICAL RESECTION. <i>Neuro-Oncology</i> , 2018, 20, vi167-vi168.	1.2	0
44	An integrated enrichment system to facilitate isolation and molecular characterization of single cancer cells from whole blood. <i>Cytometry Part A: the Journal of the International Society for Analytical Cytology</i> , 2018, 93, 1226-1233.	1.5	12
45	miRNA Profiling of Magnetic Nanopore-Isolated Extracellular Vesicles for the Diagnosis of Pancreatic Cancer. <i>Cancer Research</i> , 2018, 78, 3688-3697.	0.9	63
46	Plasma cell-free DNA (cfDNA) concentration and radiographic tumor burden in patents with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 2048-2048.	1.6	0
47	Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2017, 164, 627-638.	2.5	21
48	Flow Cytometric Methods for Circulating Tumor Cell Isolation and Molecular Analysis. <i>Advances in Experimental Medicine and Biology</i> , 2017, 994, 105-118.	1.6	4
49	Combining Machine Learning and Nanofluidic Technology To Diagnose Pancreatic Cancer Using Exosomes. <i>ACS Nano</i> , 2017, 11, 11182-11193.	14.6	196
50	Enumeration, Dielectrophoretic Capture, and Molecular Analysis of Circulating Tumor Cells. <i>Methods in Molecular Biology</i> , 2017, 1634, 193-202.	0.9	1
51	A magnetic micropore chip for rapid (< 1 hour) unbiased circulating tumor cell isolation and in situ RNA analysis. <i>Lab on A Chip</i> , 2017, 17, 3086-3096.	6.0	38
52	Emerging uses of circulating tumor DNA in advanced stage non-small cell lung cancer. <i>Annals of Translational Medicine</i> , 2017, 5, 380-380.	1.7	12
53	Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA. <i>Clinical Cancer Research</i> , 2016, 22, 5772-5782.	7.0	279
54	Circulating Tumor Cells, DNA, and mRNA: Potential for Clinical Utility in Patients With Melanoma. <i>Oncologist</i> , 2016, 21, 84-94.	3.7	20

#	ARTICLE	IF	CITATIONS
55	A novel approach for next-generation sequencing of circulating tumor cells. <i>Molecular Genetics & Genomic Medicine</i> , 2016, 4, 395-406.	1.2	21
56	Detection and isolation of circulating exosomes and microvesicles for cancer monitoring and diagnostics using micro-/nano-based devices. <i>Analyst, The</i> , 2016, 141, 450-460.	3.5	175
57	Dielectrophoretic Capture and Genetic Analysis of Single Neuroblastoma Tumor Cells. <i>Frontiers in Oncology</i> , 2014, 4, 201.	2.8	37
58	Targeting ALK in neuroblastoma—preclinical and clinical advancements. <i>Nature Reviews Clinical Oncology</i> , 2012, 9, 391-399.	27.6	148